Related Experiment Videos
[Experience with a transvenous pacemaker-cardioconverter-defibrillator without subcutaneous patch]
Insights
Implantable cardioverter-defibrillators (ICDs) prevent sudden cardiac death. A new transvenous-only lead technique using the Phylax 03 device demonstrated safety and efficacy in terminating ventricular arrhythmias.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Context:
- Sudden cardiac death (SCD) remains a significant cause of cardiovascular mortality.
- Implantable cardioverter-defibrillators (ICDs) have drastically reduced SCD incidence.
- Transvenous lead implantation is a standard but evolving technique.
Purpose:
- To evaluate the safety and efficacy of a transvenous-only lead configuration for ICD implantation in Hungary.
- To assess the performance of the Biotronik Phylax 03 device in managing malignant ventricular arrhythmias.
- To determine intraoperative defibrillation thresholds and clinical outcomes.
Summary:
- Three patients with malignant ventricular arrhythmias received ICDs using a transvenous-only lead configuration (right ventricular and superior vena cava electrodes) without a subcutaneous patch.
- The Biotronik Phylax 03 device showed low intraoperative defibrillation thresholds (6-12 J).
- During a six-month follow-up, the device successfully terminated spontaneous ventricular fibrillation and tachycardias via cardioversion-defibrillation or overdrive stimulation.
Impact:
- This study demonstrates the feasibility of a transvenous-only lead technique for ICDs in Hungary.
- The Phylax 03 biphasic system offers a safe and effective option for preventing SCD in patients with major ventricular arrhythmias.
- Low defibrillation thresholds achieved without a subcutaneous patch simplify implantation and potentially reduce complications.
Abstract:
Sudden cardiac death caused by malignant ventricular arrhythmias is one of the main causes of cardiovascular mortality. Implantation of cardioverter-defibrillators has resulted in the reduction of the incidence of sudden cardiac death caused by malignant ventricular arrhythmias from the yearly 10-30% to 1%. For the very first time in Hungary, the authors applied only transvenous lead configuration for automatic cardioverter defibrillators in three patients. The indications of the implantation were ventricular fibrillation in one case, ventricular tachycardias refractory to drug treatment in two cases. Ventricular arrhythmias were secondary to coronary heart disease in two patients, dilatative cardiomyopathy in one patient. Preoperative, intraoperative and postoperative electrophysiological studies were regularly taken. Using Biotronik Phylax 03 device with a right ventricular electrode and a superior vena cava electrode and without subcutaneous patch the intraoperative defibrillation thresholds were 6, 11 and 12 J respectively. The fractally iridium coating increases the surface of the electrodes that has a very good effect on defibrillation threshold. During a mean follow-up of six months the occurring spontaneous ventricular arrhythmias (1 ventricular fibrillation and 5 ventricular tachycardias) were terminated by Phylax 03 with cardioversion-defibrillation or overdrive stimulation. The authors' results of intraoperative testing and clinical experiences show that the Phylax 03 biphasic system due to low defibrillation thresholds without subcutaneous patch can safely be applied with only transvenous implant technique in patients with major ventricular arrhythmias to prevent sudden cardiac death and to terminate ventricular tachycardia.